Table 4.
P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 | ||
---|---|---|---|---|---|---|---|---|---|
WBC ×103/µL (4.0–10.8) | 11.25 | 6.90 | 7.18 | 4.18 | 6.14 | 8.8 | 8.51 | 8.06 | |
Neutrophils ×103/µL (1.5–8.0) | 9.40 | 3.40 | 4.93 | 2.93 | 4.58 | 5.33 | 6.43 | 4.90 | |
Lymphocytes ×103/µL (0.9–4.0) | 1.51 | 2.30 | 1.42 | 0.785 | 1.21 | 2.38 | 1.27 | 2.12 | |
IgG, mg/dL (700–1600) | 855 | 1452 | 282 † | 495 | 2119 ߇ | 362 ƒ§ | 2056 ߇ | 725 ∂# | |
IgA, mg/dL (70–400) | 227 | 80 | 55 † | 10 | 207 ߇ | 38 ƒ§ | 287 ߇ | 15 ∂# | |
IgM, mg/dL (40–230) | 2332 | 145 | 170 † | 7 | 127 ߇ | 414 ƒ§ | 155 ߇ | 228 ∂# | |
Anti-HBs IgG (>10 IU/L) | 30 IU/L | n.a. | absent | absent | 584 IU/L | absent | n.a. | n.a. | |
Anti-tetanus IgG (>0.1 IU/mL) | 0.5 IU/L | 2.5 IU/L | absent | absent | 0.6 IU/mL | absent | n.a. | 1.0 UI/L | |
CFSE-base T cells Proliferation assay | |||||||||
Anti-CD3 | normal | n.a. | normal | n.a. | n.a. | CD4+ normalCD8+ reduced | n.a. | n.a. | |
Anti-CD3 + IL-2 | normal | n.a. | normal | n.a. | n.a. | normal | n.a. | n.a. | |
PHA | reduced | n.a. | normal | n.a. | n.a. | CD4+ normalCD8+ reduced | n.a. | n.a. |
Abbreviations: Anti-HBs IgG: Anti-Hepatitis B surface Immunoglobulin G, APDS-1: Activated Phosphoinositide 3-Kinase Delta Syndrome-1, CFSE: Carboxyfluorescein succinimidyl ester, IL-2: Interleukin-2, IgA: immunoglobulin A, IgG: immunoglobulin G, IgM: immunoglobulin M, PHA: Phytohemagglutinin, WBC: White Blood Cells. Notes: n.a.: not available; †: age adjusted reference value: IgG 528–1959 mg/dL, IgA 37–257 mg/dL, IgM 49–292 mg/dL; ߇: age adjusted reference value: IgG 640–1909 mg/dL IgA 61–301 mg/dL, IgM 59–297 mg/dL; ƒ§: age adjusted reference value: IgG 633–2016 mg/dL, IgA 41–315 mg/dL, IgM 56–261 mg/dL; ∂#: age adjusted reference value: IgG 462–1710 mg/dL, IgA 27–173 mg/dL, IgM 62–257 mg/dL.